Skip to main content
SpringerLink
Log in

How safe are very low LDL cholesterol levels?

  • Practice Point
  • Published:

From Nature Clinical Practice Cardiovascular Medicine

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Cannon CP et al. (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350: 1495–1504

    Article  CAS  Google Scholar 

  2. Pitt B (2005) Low-density lipoprotein cholesterol in patients with stable coronary heart disease—is it time to shift our goals? N Engl J Med 352: 1483–1484

    Article  CAS  Google Scholar 

  3. LaRosa JC et al. (2005) Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352: 1425–1435

    Article  CAS  Google Scholar 

  4. Cholesterol Treatment Trialists' (CTT) Collaborators (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 366: 1267–1278

  5. de Lemos JA et al. (2004) Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 292: 1307–1316

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Hannah Camm, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. fellow in Cardiology,

    Sarkis B Baghdasarian & Paul D Thompson

  2. Chief of Cardiology and Director of Preventative Cardiology at the Hartford Hospital, University of Connecticut School of Medicine, Hartford, CT, USA

    Sarkis B Baghdasarian & Paul D Thompson

Authors
  1. Sarkis B Baghdasarian
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul D Thompson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paul D Thompson.

Ethics declarations

Competing interests

PD Thompson acknowledges: research support from Merck, Pfizer, and AstraZeneca; consultancy for AstraZeneca; speaking honoraria from Merck, Pfizer, KOS, AstraZeneca and Schering Plough; and stock ownership in Pfizer, Merck and Schering Plough.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Baghdasarian, S., Thompson, P. How safe are very low LDL cholesterol levels?. Nat Rev Cardiol 3, 306–307 (2006). https://doi.org/10.1038/ncpcardio0557

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpcardio0557

  • Springer Nature Limited

Search

Navigation